By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


NxStage/Fresenius Merger: FTC Update

A recommendation to approve a consent order that would allow Fresenius to move forward with its acquisition of NxStage moved from the Federal Trade Commission’s Bureau of Competition to thefeatured

Proposed NxStage/Fresenius Settlement Agreement Advanced to Commissioners

A proposed settlement agreement resolving the FTC’s Bureau of Competition’s concerns with Fresenius’s acquisition of NxStage appears to have passed to the commissioner levelfeatured

Peritoneal Divestiture Also Required in Fresenius Acquisition of NxStage

The review by the U.S. Federal Trade Commission of the acquisition of NxStage by Fresenius is on track and moving forward, according to a source familiar with the matter.featured

Fresenius Continues to Advance NxStage Acquisition

Fresenius is on track to close its acquisition of NxStage on the timeline that the parties have indicated to the market, CTFN has learned.featured

Implications of Bloodlines Sale for FTC Review of NxStage/Fresenius

NxStage agreed on July 10 to sell its bloodlines business, operated under the Medisystems name, to B. Braun Medical, subject to approval by the U.S. Federal Trade Commission and thefeatured

NxStage/Fresenius Review Lingers at FTC

Fresenius and NxStage are several months into a timing agreement with the Federal Trade Commission as the agency continues its review of the companies’ pendingfeatured

Manageable Divestiture Likely in the Works for NxStage/Fresenius Merger

Antitrust attorneys working with third parties told CTFN that a divestiture of NxStage’s bloodline tubing unit is being discussed as a condition infeatured

Fresenius Appears to Make Progress at FTC with NxStage Merger

An attorney working with a third party told CTFN that Fresenius and NxStage have strong arguments and that the companies are making their case well tofeatured

NxStage/Fresenius FTC Review Could be Helped by Recent CVS Announcement

On April 4, CVS Health announced a new initiative focused on chronic kidney disease with a planned introduction of “a truly innovative new home hemodialysis technology.” Experts featured

Fresenius Has Not Certified Compliance for NxStage Medical Acquisition

CTFN confirmed with a source close to the deal that Fresenius has not certified substantial compliance with the U.S. Federal Trade Commission’s second request, as some marketfeatured


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.